Enhancement of MHC-I Antigen Presentation via Architectural Control of pH-Responsive, Endosomolytic Polymer Nanoparticles
Journal Title: The AAPS Journal - Year 2015, Vol 17, Issue 2
Abstract
The online version of this article (doi:10.1208/s12248-014-9697-1) contains supplementary material, which is available to authorized users.
Authors and Affiliations
John T. Wilson, Almar Postma, Salka Keller, Anthony J. Convertine, Graeme Moad, Ezio Rizzardo, Laurence Meagher, John Chiefari, Patrick S. Stayton
Keywords
Related Articles
- EP ID EP680922
- DOI 10.1208/s12248-014-9697-1
- Views 55
- Downloads 0
Structure-Based Prediction of the Nonspecific Binding of Drugs to Hepatic Microsomes
For the accurate prediction of in vivo hepatic clearance or drug–drug interaction potential through in vitro microsomal metabolic data, it is essential to evaluate the fraction unbound in hepatic microsomal incub...
Human membrane transporter database: A web-accessible relational database for drug transport studies and pharmacogenomics
published July 14, 2000
Cutaneous Microdialysis: Cytokine Evidence for Altered Innate Reactivity in the Skin of Psoriasis Patients?
The online version of this article (doi:10.1208/s12248-012-9331-z) contains supplementary material, which is available to authorized users.
Plant Phytochemicals as Epigenetic Modulators: Role in Cancer Chemoprevention
In recent years, “nutri-epigenetics,” which focuses on the influence of dietary agents on epigenetic mechanism(s), has emerged as an exciting novel area in epigenetics research. Targeting of aberrant epig...
Pharmacokinetics, mass balance, and tissue distribution of a novel DNA alkylating agent, VNP40101M, in rats
VNP40101M (1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(2 methylamino)carbonyl] hydrazine), a novel DNA alkylating agent, is currently under clinical development for the treatment of cancer in Phase I clinical trials. T...